DEFINE Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
==Objective== | ==Objective== | ||
The objective of this trial is to study the therapeutic and adverse effect of anacetrapib, a CETP inhibitor, alone and with statin. | |||
==Timeline== | ==Timeline== | ||
====Start Date==== | ====Start Date==== | ||
| Line 11: | Line 11: | ||
==Methods== | ==Methods== | ||
* Phase III trial | |||
* Prospective, randomized, multicenter, placebo-controlled double-blind clinical trial that recuited 1,623 patients. | |||
* Inclusion criteria: Age between 18-80 years, LDL-C < 100 mg/dL and coronary heart disease or risk equivalent , patient receiving statin therapy with or without other anti-lipidemics, HDL < 60 mg/dL, triglycerides < 400 mg/dL, abstinence or use of at least 2 effective contraceptive methods, be at least 75% compliant during run-in phase | |||
* Exclusion criteria: NYHA class III or IV heart failure, any of the following events within 3 months: Uncontrolled arrhythmias, myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, unstable angina, or stroke, LDL-C<50 mg/dL, uncontrolled hypertension defined as SBP ≥ 160 mmHg / DBP≥ 100 mmHg for non-diabetics or SBP ≥ 150 mmHg / DBP ≥ 90 mmHg for diabetics, CPK or liver function tests twice the upper normal limit, active or chronic hepatic or biliary disease, renal failure with eGFR < 30 mL/min/1.73 m2, diabetes mellitus diagnosed within 3 months or HbA1c > 8.5%, TSH below or 20% above normal limit, homozygous familial hypercholesterolemia, type I and type II hyperlipidemia , currently on warfarin, systemic corticosteroids, anabolic steroids, or any drug that potently affects CYP3A4. | |||
* Run-in phase: 2 weeks | |||
* Two arms of the study: anacetrapib 100 mg daily or placebo for 76 weeks | |||
* Primary end points: Percent change in LDL after 24 weeks, adverse experiences including cardiovascular end points, other lab values, ECG changes, vital sign and physical examination assessments after 76 weeks of treatment. | |||
* Secondary end points: Change in HDL, total cholesterol, triglyceride, CRP apo A-I, A-II, B, C-III, and E, lipoprotein(a) and ratios of total cholesterol/HDL, LDL/HDL, apo B/ apo A-I, and LDL/apo B after 24 and 76 weeks of treatment * | |||
* Cardiovascular end points are defined as cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina. | |||
==Results== | ==Results== | ||
Revision as of 12:38, 18 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
DEFINE Trial On the Web |
|
American Roentgen Ray Society Images of DEFINE Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
The objective of this trial is to study the therapeutic and adverse effect of anacetrapib, a CETP inhibitor, alone and with statin.
Timeline
Start Date
April 2008
Methods
- Phase III trial
- Prospective, randomized, multicenter, placebo-controlled double-blind clinical trial that recuited 1,623 patients.
- Inclusion criteria: Age between 18-80 years, LDL-C < 100 mg/dL and coronary heart disease or risk equivalent , patient receiving statin therapy with or without other anti-lipidemics, HDL < 60 mg/dL, triglycerides < 400 mg/dL, abstinence or use of at least 2 effective contraceptive methods, be at least 75% compliant during run-in phase
- Exclusion criteria: NYHA class III or IV heart failure, any of the following events within 3 months: Uncontrolled arrhythmias, myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft, unstable angina, or stroke, LDL-C<50 mg/dL, uncontrolled hypertension defined as SBP ≥ 160 mmHg / DBP≥ 100 mmHg for non-diabetics or SBP ≥ 150 mmHg / DBP ≥ 90 mmHg for diabetics, CPK or liver function tests twice the upper normal limit, active or chronic hepatic or biliary disease, renal failure with eGFR < 30 mL/min/1.73 m2, diabetes mellitus diagnosed within 3 months or HbA1c > 8.5%, TSH below or 20% above normal limit, homozygous familial hypercholesterolemia, type I and type II hyperlipidemia , currently on warfarin, systemic corticosteroids, anabolic steroids, or any drug that potently affects CYP3A4.
- Run-in phase: 2 weeks
- Two arms of the study: anacetrapib 100 mg daily or placebo for 76 weeks
- Primary end points: Percent change in LDL after 24 weeks, adverse experiences including cardiovascular end points, other lab values, ECG changes, vital sign and physical examination assessments after 76 weeks of treatment.
- Secondary end points: Change in HDL, total cholesterol, triglyceride, CRP apo A-I, A-II, B, C-III, and E, lipoprotein(a) and ratios of total cholesterol/HDL, LDL/HDL, apo B/ apo A-I, and LDL/apo B after 24 and 76 weeks of treatment *
- Cardiovascular end points are defined as cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina.